White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

28 Abstract

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

48

49 1. Introduction

50 By November 2022, 94% of the US population was estimated to have been infected by SARS-CoV-2 at 51 least once (Klaassen et al., 2022). This proportion continues to rise as COVID-19 remains as an important 52 public health threat. Some people recover quickly after the initial infection, while others (between 10% to 53 30%) continue to experience symptoms even months after the initial infection (Herman et al., 2022). Long 54 COVID is defined by the World Health Organization (WHO) as persistent symptoms and/or long-term 55 complications following a probable or confirmed SARS-CoV-2 infection, usually 3 months from acute

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

104 2. Our approach to predicting long COVID

105 Several features of long COVID make identifying positive cases using claims and EHR data challenging. 106 First, some symptoms of long COVID may or may not be detectable, depending on which diagnostic test 107 is used (Mancini et al., 2021). Second, due to early skepticism within the medical profession about the 108 existence of COVID-19, there have been significant informal, patient-led efforts to report and track the 109 various symptoms of long COVID (Patient Led Research Collaborative, 2023). Third, symptoms 110 occurring during the long COVID episode must be separated from the initial episode of COVID itself, 111 which may vary in length and severity. Fourth, like other medical conditions, a claims-based definition 112 must be clinically relevant with respect to disease severity, and account for health conditions a patient 113 may have had prior to their COVID and long COVID episodes. 114 Given these challenges, we tested several approaches to defining long COVID using data from the N3C 115 Enclave. We first defined a six-month lookback & look-forward window around each patients' index 116 COVID-19 episode and limited our sample to patients who have healthcare utilization (defined as having 117 a condition recorded in the N3C database) prior to, and after, these windows. This allowed us to 118 accurately classify a lack of healthcare utilization during the lookback or look-forward windows as true 119 non-utilization, as opposed to a patient death, relocation, or otherwise missing data. We then identified all 120 OMOP concept ID condition codes that appear on a patient's record between 90 and 180 days following 121 their index COVID-19 diagnosis. Excluding conditions recorded within 90 days after an initial COVID-122 19 diagnosis ensured that we do not flag symptoms of COVID-19 as symptoms of long COVID. From the 123 resulting set of symptoms, we removed any symptoms that appeared on a patient's record during their 124 lookback window. A drawback of this approach is that it reduces the likelihood that we detect long 125 COVID cases among people with chronic conditions or comorbidities, who are actually most likely to 126 contract long COVID. We additionally removed any symptoms during the look-forward period that do 127 not appear on the list of 76 conditions in the N3C Long COVID OMOP condition code set. The 128 remaining symptoms were considered as the patient's long COVID symptom burden.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

147 3. Characteristics of Sample

- 148 We used the N3C de-identified "tier 2 access" data set.¹ A limitation of our analysis is that the Patient
- 149 Severity and Scores dataset, condition occurrence, and drug exposure datasets are frequently updated

 1 Tire 2 access is the patient level EHR data where 17 patient identifier variables are removed and longitudinal data is data-shifted to safeguard privacy (Haendel et al., 2021). We selected patients for the analysis from the Patient Severity and Scores dataset (Release-v70-2022-03-19). The dataset contains patient level information from all sites. N3C identifies positive COVID-19 cases through their COVID-19 Phenotype Inclusion Criteria (Pfaff, 2022). Though this did not factor into our analysis, another feature of the N3C data is a 1:2 case to control ratio of patients with identifies lab-confirmed, suspected, and possible cases of COVID-19 to patients who have been screen and tested negative for COVID-19. In addition, we linked patient ids from the Patient Severity and Scores dataset with

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

169 Missing or Unknown.

 2^2 For selecting the patients how has conditions occurrences within 6 months preceding and proceeding diagnosis, we used the condition occurrence dataset (Release-v70-2022-03-19)

two additional datasets provided in N3C, the condition occurrence dataset (Release-v70-2022-03-19) and the drug exposures dataset (Release-v70-2022-03-19) to provide additional longitudinal information about the patients in the database. These condition occurrence dataset records diagnosis, signs, and symptoms of conditions and drug exposure dataset records introduction of drugs into the body of the patient overtime (Observational Health Data Sciences and Informatics, 2018).

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

193 vaccination variable, we choose not to include vaccination in our modeling.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

194 4. Summary statistics for Cognitive, Fatigue, and Respiratory variations of Long COVID

195 We examined long COVID by three symptom clusters -- cognitive, fatigue, and respiratory -- as defined 196 by the Global Burden of Disease Long COVID Collaborators (Global Burden of Disease Long COVID 197 Collaborators, 2022). We classified patients as being positive for the individual symptom clusters if the 198 patients had a qualifying symptom present between 3 to 6 months after having a lab confirmed case of 199 COVID-19 and that symptom was not reported in the 6 months preceding their lab confirmed case of 200 COVID-19. For a full list of the symptoms and OMOP codes we used as qualifying cognitive, fatigue, 201 and respiratory long COVID symptoms, see Appendix A2, A3, and A4 respectively. Then we focused our 202 analysis on the three separate symptom clusters and predicted the risk of a patient having had each 203 symptom cluster of long COVID systems. 204 The fatigue long COVID symptom cluster was the most common in our sample with 4.7% (n = 57,483) of 205 all patients, followed by respiratory cluster with 2.5% ($n = 30,668$) of our sample, and the cognitive 206 symptom cluster with only 0.2% $(n = 2.937)$ of the sample (Table 1). In general, for all three symptom 207 clusters, there was an age gradient where patients in younger age groups have lower rates of symptom 208 clusters than patients in older groups. Female patients had higher rates (5.7%) of the fatigue symptom 209 cluster than male patients (3.3%) and there was no difference in rates between the sexes for the cognitive 210 symptom clusters (female $= 0.3\%$; male $= 0.2\%$) and respiratory (female $= 2.6\%$; male $= 2.3\%$). Black 211 and White patients had higher prevalence than other race groups for all three symptom clusters. There 212 was not a meaningful difference in prevalence by ethnicity. Patients who had cognitive, fatigue, and 213 respiratory symptom clusters had higher average CCI scores than those who did not experience said 214 symptom clusters. The highest average CCI scores were patients who had cognitive cluster symptoms 215 (mean = 2.7), compared to fatigue (mean = 1.4) and respiratory (mean = 1.4) symptom clusters. For other 216 variables we did not observe large differences between groups.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

217 5. Predictive model for long COVID outcomes

218 **Model training methods**

219 We trained two types of machine learning models (a binary logistic regression model and a binary random 220 forest model) on all three long COVID clusters separately: respiratory, fatigue, and cognitive. We used a 221 70-30 train-test split, resulting in 863,883 training observations and 370,236 test observations. To 222 accommodate for long COVID being a rare outcome in all three of our clusters, we trained all models on 223 down sampled data and tested them on the original, unbalanced data. To create the down sampled training 224 data, we took five bootstrapped samples with replacement. Each bootstrapped sample had an equal 225 number of positive and negative cases, which was also equal to the total number of positive cases in the 226 original training data.

227 **Model performance**

228 The random forest model outperformed the logistic regression model at predicting the respiratory and 229 cognitive clusters, but the logistic regression model slightly outperformed the random forest model at 230 predicting the fatigue outcome (Table 2). In all six models, the AUC remained fairly consistent between 231 the train and test data, but the model precision (a measure of how often a model's positive predictions are 232 correct) dropped quite dramatically between the train and test data. This could be because long COVID 233 was a rare outcome, or that there is low signal in the data.

234 **Covariates**

235 To measure feature importance, we considered coefficient values for the binary logistic regression models 236 and impurity-based variable importance scores for the random forest models (Tables 3 and 4). Among our 237 six models, there were some variations in which covariates were most predictive. The CCI score was the 238 most important feature in all three clusters for the random forest models. However, for the binary logistic 239 regression models, all three clusters had different most important features (Table 3). For the respiratory 240 cluster, the two most important features are belonging to the $0 - 9$ age group and being a current or 241 former smoker. For the fatigue cluster, the two most important features are belonging to the $0 - 9$ age

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

242 group and being male. Finally, for the cognitive cluster, the two most important features are being 80

243 vears old or older and belonging to the $70 - 79$ age group.

244 **Comparisons with other long COVID predictive models**

- 245 One challenge in comparing models is that there is not a consistent definition of long COVID that is
- 246 universally accepted. The two papers described below offer two alternative definitions of long COVID.
- 247 One study also uses data from N3C to predict outcomes of long COVID. The authors consider visiting a
- 248 long COVID clinic as an indicator that a patient has long COVID (Pfaff, 2022). This is a narrower
- 249 definition of long COVID than our definition in this study. Their XGBoost model results in an AUC of
- 250 0.92 for all patients in their sample, 0.90 for hospitalized patients, and 0.85 for non-hospitalized patients.
- 251 The simplicity of their measure could explain why their results are better than the results from our

252 models. However, there are also drawbacks to defining long COVID as a visit to a long COVID clinic. a

- 253 long COVID clinic is a very specific type of care and someone's long COVID symptoms have to be
- 254 pretty severe to be referred to a long COVID clinic. Thus, the Pfaff definition undercounts the number of
- 255 patients with long COVID especially patients with more mild symptoms of long COVID.
- 256 Another study used age, sex, and the number of symptoms a patient experienced in the first week of
- 257 infection to classify duration of COVID-19 as either short (less than 10 days) or long (28 days or more,
- 258 which is shorter than the WHO recommendation) using k-means clustering (Sudre et al., 2021). The
- 259 authors analyzed self-reported data from 4,182 cases of COVID-19 through the COVID Symptom Study
- 260 app and used a random forest model and a logistic regression model to predict long COVID, as defined by
- 261 having symptoms for 28 days or longer. The random forest model, which included first week symptoms
- 262 and other comorbidities, performed moderately well with an AUC of 0.768. The logistic regression model
- 263 was much simpler and included only age, sex, and number of symptoms in the first week, with an AUC of
- 264 0.767. One key difference between Sudre et al and our model is that Sudre et al included the number of
- 265 symptoms in the first week which is likely a proxy for identify which patients had more severe initial
- 266 COVID infections, whereas our model had limited variables representing the severity of initial infection.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

267 6. Apply the fair machine learning framework to the long COVID predictive models

286 disparate impact remover (a preprocessing technique that edits input values to increase fairness between 287 groups), reweighting (producing weights for each subgroup for each outcome class to achieve statistical 288 parity), and resampling (oversampling or under-sampling to achieve statistical parity). We will compare 289 the effects of different mitigation techniques and discuss their impact on the balance between model 290 performance and fairness metrics. The method maximizing model predictive performance may be 291 different from the method achieving the highest fairness metrics. We will discuss the trade-off between

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

292 model performance and fairness in the context of using real-world EHR data to develop predictive models

293 for long COVID.

294 Conclusion

295 **Overarching takeaways regarding model performance**

296 In this study, we explored the feasibility to train a predictive model to provide insights into the risk

297 factors for long COVID. We leveraged a diverse and harmonized electronic health record data source and

- 298 applied minimum filters to build a model with high potential to be applied to general population. After
- 299 using techniques to handle unbalanced sample, our predictive models achieved moderate performance
- 300 accuracy (AUC 0.599 0.730 for the random forest models, AUC 0.602 0.734 for the logistic
- 301 regression models). It was interesting to observe that logistic regression models have comparable
- 302 performance to random forest models, potentially because we included relatively limited number of
- 303 predictors that are easy to acquire. Other predictive models developed in the past had stronger
- 304 performances but they either leveraged clinical factors that can be hard to acquire such as blood oxygen,
- 305 blood pH (Bennett et al., 2021), or they limited the population to a small and relatively homogenous
- 306 groups of people, such as users of the COVID Symptom Study app or patients visiting a long COVID
- 307 clinic (Pfaff, 2022; Sudre et al., 2021).

308 **Comparison with 19&Me severe COVID risk model**

309 Previously we leveraged the same data source (N3C) and machine learning models to build a predictive

310 model for severe COVID-19 outcomes. Severe COVID-19 outcome is defined as having a score of 6 or

- 311 above using the Clinical Progression Scale (CPS) established by the World Health Organization for
- 312 COVID-19 clinical research (Marshall et al., 2020). In a sample of 864,8080 COVID-19 positive
- 313 patients, 15,401 (1.75%) has this outcome. Many risk factors are related to elevated COVID-19 risk, and
- 314 others have published machine learning models that achieve high predictive performance (AUROC =
- 315 0.87) using a long list of predictors including demographics (age/sex/race), health conditions
- 316 (comorbidities) and clinical characteristics (blood pH, respiratory rate, oxygen saturation…). We limit

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

337 Acknowledgements

- 338 This work is supported by Mathematica.
- 339 N3C Attribution

340 The analyses described in this manuscript were conducted with data or tools accessed through the

341 NCATS N3C Data Enclave https://covid.cd2h.org and N3C Attribution & Publication Policy v 1.2-2020-

342 08-25b supported by NCATS Contract No. 75N95023D00001, Axle Informatics Subcontract: NCATS-

343 P00438-B, and [insert additional funding agencies or sources and reference numbers as declared by the

344 contributors in their form response above]. This research was possible because of the patients whose

- 345 information is included within the data and the organizations (https://ncats.nih.gov/n3c/resources/data-
- 346 contribution/data-transfer-agreement-signatories) and scientists who have contributed to the on-going
- 347 development of this community resource [https://doi.org/10.1093/jamia/ocaa196].
- 348

349 Disclaimer The N3C Publication committee confirmed that this manuscript msid:1865.948 is in

350 accordance with N3C data use and attribution policies; however, this content is solely the responsibility of

- 351 the authors and does not necessarily represent the official views of the National Institutes of Health or the
- 352 N3C program.
- 353
- 354 IRB

355 The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol #

- 356 IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the
- 357 authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources.
- 358
- 359 Individual Acknowledgements For Core Contributors
- 360 We gratefully acknowledge the following core contributors to N3C:
- 361

362 Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha,

363 Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew Southerland, Andrew T. Girvin, Anita Walden,

364 Anjali A. Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, Caleb

365 Alexander, Carolyn Bramante, Cavin Ward-Caviness, Charisse Madlock-Brown, Christine Suver,

366 Christopher Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman,

367 Davera Gabriel, David A. Eichmann, Diego Mazzotti, Don Brown, Eilis Boudreau, Elaine Hill, Elizabeth

- 368 Zampino, Emily Carlson Marti, Emily R. Pfaff, Evan French, Farrukh M Koraishy, Federico Mariona,
- 369 Fred Prior, George Sokos, Greg Martin, Harold Lehmann, Heidi Spratt, Hemalkumar Mehta, Hongfang
- 370 Liu, Hythem Sidky, J.W. Awori Hayanga, Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica
- 371 Islam, Jin Ge, Joel Gagnier, Joel H. Saltz, Joel Saltz, Johanna Loomba, John Buse, Jomol Mathew, Joni
- 372 L. Rutter, Julie A. McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell,
- 373 Kellie M. Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Dwain Cato, Kimberly Murray, Kristin
- 374 Kostka, Lavance Northington, Lee Allan Pyles, Leonie Misquitta, Lesley Cottrell, Lili Portilla, Mariam

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

- 375 Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Mary Morrison Saltz, Matvey B. Palchuk,
- 376 Melissa A. Haendel, Meredith Adams, Meredith Temple-O'Connor, Michael G. Kurilla, Michele Morris,
- 377 Nabeel Qureshi, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan, Patricia A. Francis,
- 378 Penny Wung Burgoon, Peter Robinson, Philip R.O. Payne, Rafael Fuentes, Randeep Jawa, Rebecca
- 379 Erwin-Cohen, Rena Patel, Richard A. Moffitt, Richard L. Zhu, Rishi Kamaleswaran, Robert Hurley,
- 380 Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel Bozzette, Sandeep Mallipattu, Satyanarayana
- 381 Vedula, Scott Chapman, Shawn T. O'Neil, Soko Setoguchi, Stephanie S. Hong, Steve Johnson, Tellen D.
- 382 Bennett, Tiffany Callahan, Umit Topaloglu, Usman Sheikh, Valery Gordon, Vignesh Subbian, Warren A.
- 383 Kibbe, Wenndy Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang.
- 384 Details of contributions available at covid.cd2h.org/core-contributors
- 385
- 386 Data Partners with Released Data

387 The following institutions whose data is released or pending:

388

389 Available: Advocate Health Care Network — UL1TR002389: The Institute for Translational Medicine 390 (ITM) • Aurora Health Care Inc — UL1TR002373: Wisconsin Network For Health Research • Boston 391 University Medical Campus — UL1TR001430: Boston University Clinical and Translational Science 392 Institute • Brown University — U54GM115677: Advance Clinical Translational Research (Advance-393 CTR) • Carilion Clinic — UL1TR003015: iTHRIV Integrated Translational health Research Institute of 394 Virginia • Case Western Reserve University — UL1TR002548: The Clinical & Translational Science 395 Collaborative of Cleveland (CTSC) • Charleston Area Medical Center — U54GM104942: West Virginia 396 Clinical and Translational Science Institute (WVCTSI) • Children's Hospital Colorado — 397 UL1TR002535: Colorado Clinical and Translational Sciences Institute • Columbia University Irving 398 Medical Center — UL1TR001873: Irving Institute for Clinical and Translational Research • Dartmouth 399 College — None (Voluntary) Duke University — UL1TR002553: Duke Clinical and Translational 400 Science Institute • George Washington Children's Research Institute — UL1TR001876: Clinical and 401 Translational Science Institute at Children's National (CTSA-CN) • George Washington University — 402 UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN) • Harvard 403 Medical School — UL1TR002541: Harvard Catalyst • Indiana University School of Medicine — 404 UL1TR002529: Indiana Clinical and Translational Science Institute • Johns Hopkins University — 405 UL1TR003098: Johns Hopkins Institute for Clinical and Translational Research • Louisiana Public 406 Health Institute — None (Voluntary) • Loyola Medicine — Loyola University Medical Center • Loyola 407 University Medical Center — UL1TR002389: The Institute for Translational Medicine (ITM) • Maine 408 Medical Center — U54GM115516: Northern New England Clinical & Translational Research (NNE-409 CTR) Network • Mary Hitchcock Memorial Hospital & Dartmouth Hitchcock Clinic — None (Voluntary) 410 • Massachusetts General Brigham — UL1TR002541: Harvard Catalyst • Mayo Clinic Rochester — 411 UL1TR002377: Mayo Clinic Center for Clinical and Translational Science (CCaTS) • Medical University 412 of South Carolina — UL1TR001450: South Carolina Clinical & Translational Research Institute (SCTR) 413 • MITRE Corporation — None (Voluntary) • Montefiore Medical Center — UL1TR002556: Institute for 414 Clinical and Translational Research at Einstein and Montefiore • Nemours — U54GM104941: Delaware 415 CTR ACCEL Program • NorthShore University HealthSystem — UL1TR002389: The Institute for 416 Translational Medicine (ITM) • Northwestern University at Chicago — UL1TR001422: Northwestern 417 University Clinical and Translational Science Institute (NUCATS) • OCHIN — INV-018455: Bill and

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

418 Melinda Gates Foundation grant to Sage Bionetworks • Oregon Health & Science University — 419 UL1TR002369: Oregon Clinical and Translational Research Institute • Penn State Health Milton S. 420 Hershey Medical Center — UL1TR002014: Penn State Clinical and Translational Science Institute • 421 Rush University Medical Center — UL1TR002389: The Institute for Translational Medicine (ITM) • 422 Rutgers, The State University of New Jersey — UL1TR003017: New Jersey Alliance for Clinical and 423 Translational Science • Stony Brook University — U24TR002306 • The Alliance at the University of 424 Puerto Rico, Medical Sciences Campus — U54GM133807: Hispanic Alliance for Clinical and 425 Translational Research (The Alliance) • The Ohio State University — UL1TR002733: Center for Clinical 426 and Translational Science • The State University of New York at Buffalo — UL1TR001412: Clinical and 427 Translational Science Institute • The University of Chicago — UL1TR002389: The Institute for 428 Translational Medicine (ITM) • The University of Iowa — UL1TR002537: Institute for Clinical and 429 Translational Science • The University of Miami Leonard M. Miller School of Medicine — 430 UL1TR002736: University of Miami Clinical and Translational Science Institute • The University of 431 Michigan at Ann Arbor — UL1TR002240: Michigan Institute for Clinical and Health Research • The 432 University of Texas Health Science Center at Houston — UL1TR003167: Center for Clinical and 433 Translational Sciences (CCTS) • The University of Texas Medical Branch at Galveston — 434 UL1TR001439: The Institute for Translational Sciences • The University of Utah — UL1TR002538: 435 Uhealth Center for Clinical and Translational Science • Tufts Medical Center — UL1TR002544: Tufts 436 Clinical and Translational Science Institute • Tulane University — UL1TR003096: Center for Clinical 437 and Translational Science • The Queens Medical Center — None (Voluntary) • University Medical 438 Center New Orleans — U54GM104940: Louisiana Clinical and Translational Science (LA CaTS) Center 439 • University of Alabama at Birmingham — UL1TR003096: Center for Clinical and Translational Science 440 • University of Arkansas for Medical Sciences — UL1TR003107: UAMS Translational Research 441 Institute • University of Cincinnati — UL1TR001425: Center for Clinical and Translational Science and 442 Training • University of Colorado Denver, Anschutz Medical Campus — UL1TR002535: Colorado 443 Clinical and Translational Sciences Institute • University of Illinois at Chicago — UL1TR002003: UIC 444 Center for Clinical and Translational Science • University of Kansas Medical Center — UL1TR002366: 445 Frontiers: University of Kansas Clinical and Translational Science Institute • University of Kentucky — 446 UL1TR001998: UK Center for Clinical and Translational Science • University of Massachusetts Medical 447 School Worcester — UL1TR001453: The UMass Center for Clinical and Translational Science 448 (UMCCTS) • University Medical Center of Southern Nevada — None (voluntary) • University of 449 Minnesota — UL1TR002494: Clinical and Translational Science Institute • University of Mississippi 450 Medical Center — U54GM115428: Mississippi Center for Clinical and Translational Research (CCTR) • 451 University of Nebraska Medical Center — U54GM115458: Great Plains IDeA-Clinical & Translational 452 Research • University of North Carolina at Chapel Hill — UL1TR002489: North Carolina Translational 453 and Clinical Science Institute • University of Oklahoma Health Sciences Center — U54GM104938: 454 Oklahoma Clinical and Translational Science Institute (OCTSI) • University of Pittsburgh — 455 UL1TR001857: The Clinical and Translational Science Institute (CTSI) • University of Pennsylvania — 456 UL1TR001878: Institute for Translational Medicine and Therapeutics • University of Rochester — 457 UL1TR002001: UR Clinical & Translational Science Institute • University of Southern California — 458 UL1TR001855: The Southern California Clinical and Translational Science Institute (SC CTSI) • 459 University of Vermont — U54GM115516: Northern New England Clinical & Translational Research 460 (NNE-CTR) Network • University of Virginia — UL1TR003015: iTHRIV Integrated Translational health 461 Research Institute of Virginia • University of Washington — UL1TR002319: Institute of Translational 462 Health Sciences • University of Wisconsin-Madison — UL1TR002373: UW Institute for Clinical and 463 Translational Research • Vanderbilt University Medical Center — UL1TR002243: Vanderbilt Institute

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

464 for Clinical and Translational Research • Virginia Commonwealth University — UL1TR002649: C. 465 Kenneth and Dianne Wright Center for Clinical and Translational Research • Wake Forest University 466 Health Sciences — UL1TR001420: Wake Forest Clinical and Translational Science Institute • 467 Washington University in St. Louis — UL1TR002345: Institute of Clinical and Translational Sciences • 468 Weill Medical College of Cornell University — UL1TR002384: Weill Cornell Medicine Clinical and 469 Translational Science Center • West Virginia University — U54GM104942: West Virginia Clinical and 470 Translational Science Institute (WVCTSI) Submitted: Icahn School of Medicine at Mount Sinai —
471 ULITR001433: ConduITS Institute for Translational Sciences • The University of Texas Health Scie UL1TR001433: ConduITS Institute for Translational Sciences • The University of Texas Health Science 472 Center at Tyler — UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • University of 473 California, Davis — UL1TR001860: UCDavis Health Clinical and Translational Science Center • 474 University of California, Irvine — UL1TR001414: The UC Irvine Institute for Clinical and Translational 475 Science (ICTS) • University of California, Los Angeles — UL1TR001881: UCLA Clinical Translational 476 Science Institute • University of California, San Diego — UL1TR001442: Altman Clinical and 477 Translational Research Institute • University of California, San Francisco — UL1TR001872: UCSF 478 Clinical and Translational Science Institute I NYU Langone Health Clinical Science Core, Data Resource
479 Core, and PASC Biorepository Core — OTA-21-015A: Post-Acute Sequelae of SARS-CoV-2 Infection 479 Core, and PASC Biorepository Core — OTA-21-015A: Post-Acute Sequelae of SARS-CoV-2 Infection 480 Initiative (RECOVER)□ Pending: Arkansas Children's Hospital — UL1TR003107: UAMS Translational
481 Research Institute • Baylor College of Medicine — None (Voluntary) • Children's Hospital of 481 Research Institute • Baylor College of Medicine — None (Voluntary) • Children's Hospital of 482 Philadelphia — UL1TR001878: Institute for Translational Medicine and Therapeutics • Cincinnati 483 Children's Hospital Medical Center — UL1TR001425: Center for Clinical and Translational Science and 484 Training • Emory University — UL1TR002378: Georgia Clinical and Translational Science Alliance • 485 HonorHealth — None (Voluntary) • Loyola University Chicago — UL1TR002389: The Institute for 486 Translational Medicine (ITM) • Medical College of Wisconsin — UL1TR001436: Clinical and 487 Translational Science Institute of Southeast Wisconsin • MedStar Health Research Institute — None 488 (Voluntary) • Georgetown University — UL1TR001409: The Georgetown-Howard Universities Center 489 for Clinical and Translational Science (GHUCCTS) • MetroHealth — None (Voluntary) • Montana State 490 University — U54GM115371: American Indian/Alaska Native CTR • NYU Langone Medical Center — 491 UL1TR001445: Langone Health's Clinical and Translational Science Institute • Ochsner Medical Center 492 — U54GM104940: Louisiana Clinical and Translational Science (LA CaTS) Center • Regenstrief 493 Institute — UL1TR002529: Indiana Clinical and Translational Science Institute • Sanford Research — 494 None (Voluntary) • Stanford University — UL1TR003142: Spectrum: The Stanford Center for Clinical 495 and Translational Research and Education • The Rockefeller University — UL1TR001866: Center for 496 Clinical and Translational Science • The Scripps Research Institute — UL1TR002550: Scripps Research 497 Translational Institute • University of Florida — UL1TR001427: UF Clinical and Translational Science 498 Institute • University of New Mexico Health Sciences Center — UL1TR001449: University of New 499 Mexico Clinical and Translational Science Center • University of Texas Health Science Center at San 500 Antonio — UL1TR002645: Institute for Integration of Medicine and Science • Yale New Haven Hospital 501 — UL1TR001863: Yale Center for Clinical Investigation

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

502 References

- 503 Bennett, T. D., Moffitt, R. A., Hajagos, J. G., Amor, B., Anand, A., Bissell, M. M., Bradwell, K. R.,
- 504 Bremer, C., Byrd, J. B., Denham, A., DeWitt, P. E., Gabriel, D., Garibaldi, B. T., Girvin, A. T.,
- 505 Guinney, J., Hill, E. L., Hong, S. S., Jimenez, H., Kavuluru, R., … National COVID Cohort
- 506 Collaborative (N3C) Consortium. (2021). Clinical Characterization and Prediction of Clinical
- 507 Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID
- 508 Cohort Collaborative. *JAMA Network Open*, *4*(7), e2116901.
- 509 https://doi.org/10.1001/jamanetworkopen.2021.16901
- 510 Blacketer, C. (2021, January 11). *Chapter 4 The Common Data Model*. The Book of OHDSI.
- 511 https://ohdsi.github.io/TheBookOfOhdsi/
- 512 CDC. (2022, June 22). *Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long*
- 513 *COVID."* https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm
- 514 CDC. (2023, January 4). *Long COVID Household Pulse Survey—COVID-19*.
- 515 https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm
- 516 Cohen, J., & van der Meulen Rodgers, Y. (2023). An intersectional analysis of long COVID prevalence.
- 517 *International Journal for Equity in Health*, *22*, 261. https://doi.org/10.1186/s12939-023-02072-5
- 518 Crook, H., Raza, S., Nowell, J., Young, M., & Edison, P. (2021). Long covid—Mechanisms, risk factors,

519 and management. *BMJ*, *374*, n1648. https://doi.org/10.1136/bmj.n1648

- 520 Cutler, D. (2022, July 22). *The Economic Cost of Long COVID: An Update*.
- 521 https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf
- 522 Cutler, D. M., & Summers, L. H. (2020). The COVID-19 Pandemic and the \$16 Trillion Virus. *JAMA*,
- 523 *324*(15), 1495–1496. https://doi.org/10.1001/jama.2020.19759
- 524 Glasheen, W. P., Cordier, T., Gumpina, R., Haugh, G., Davis, J., & Renda, A. (2019). Charlson
- 525 Comorbidity Index: ICD-9 Update and ICD-10 Translation. *American Health & Drug Benefits*,
- 526 *12*(4), Article 4.

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

DRAFT 05/31/24 Mathematica® $\ln 21$

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

- 579 Ntatsaki, E., & Vassiliou, V. S. (2023). Risk Factors Associated With Post−COVID-19
- 580 Condition: A Systematic Review and Meta-analysis. *JAMA Internal Medicine*.
- 581 https://doi.org/10.1001/jamainternmed.2023.0750
- 582 Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020). COVID-19 and Racial/Ethnic
- 583 Disparities. *JAMA*, *323*(24), 2466–2467. https://doi.org/10.1001/jama.2020.8598
- 584 World Health Organization. (2021, October 6). *A clinical case definition of post COVID-19 condition by*
- 585 *a Delphi consensus, 6 October 2021*. https://www.who.int/publications-detail-redirect/WHO-
- 586 2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1

587

588 **Tables**

589 Table 1: Analytic Sample

590 ‡ To comply with N3C policy, counts below 20 are displayed as < 20, and in this case, additional values must be skewed by up to 5 to render it

591 impossible to back-calculate precise counts fewer than 20 for the following categories: Age Group 0-9, Sex Other, Native Hawaiian or Pacific

592 Islander, Race Other, and Pregnant.

593 ¶ This proportion is one of the two columns that sum up to one. Reporting it would enable the calculation of a cell size < 20. Therefore we mark it 594 as too small to quantitatively report.

595 Abbreviations: SD: standard deviation; CCI: Charlson Comorbidity Index

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

596 Table 2: Model Performance Results

597 Abbreviations: AUC: Area under the curve

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

598 Table 3: Coefficient Values for the Binary Logistic Regression Models

599 Abbreviations: CCI: Charlson Comorbidity Index

White Paper: Can longitudinal electronic health record data identify patients at higher risk of developing long COVID?

600 Table 4: Impurity-Based Variable Importance Scores for the Random Forest Models

601 Abbreviations: CCI: Charlson Comorbidity Index